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Lipid A4E10), originally derived from HIV-1-infected patients, are important, but rare,
mAbs that exhibit broad cross-clade neutralizing activities against HIV-1. In addition to peptide sequences on
the gp41 envelope protein, both antibodies reportedly also bound speciﬁcally to several phospholipid
antigens. However, the phospholipid binding property of 2F5 has been disputed and, because of uncertainly
regarding phospholipid binding, the modeling of neutralizing mechanisms has been difﬁcult. To explore this
issue, we examined the binding of 4E10 and 2F5 to a broad range of lipid antigens by ELISA. 4E10 and 2F5
both bound to a variety of puriﬁed phospholipids, and 4E10 bound, but 2F5 did not bind, to cardiolipin. Both
mAbs also bound to a sulfated glycolipid, sulfogalactosyl ceramide (sulfatide), and to two neutral glycolipids,
galactosyl ceramide and glucosyl ceramide, but not to other galactosyl glycolipids. 4E10, but not 2F5, also
bound to cholesterol, although both mAbs bound to squalene. Interestingly, 4E10, but not 2F5, exhibited
striking binding to lipid A, the lipid moiety of Gram-negative bacterial lipopolysaccharide. The binding
properties of 4E10 to phospholipids, sulfatide, cholesterol, squalene, and lipid A were similar to those of a
neutralizing murine mAb (WR304) induced by liposomes containing phosphatidylinositol phosphate and
lipid A, although WR304 did not bind to neutral glycolipids. The discovery of a binding speciﬁcity of 4E10 for
lipid A, a widely used vaccine adjuvant, suggests that innate immunity stimulated by lipid A could have
played a role for induction of multispeciﬁc antibodies that simultaneously recognize both HIV-1 protein and
lipid antigens.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionThe quest for an effective vaccine to HIV-1 is at a crucial, and
perhaps historic, juncture in which analysis of available immunolo-
gical models requires careful attention, particularly as they relate to
induction of neutralizing antibodies [1]. A small number of human
mAbs that broadly neutralize primary isolates of HIV-1 have served as
important models of antibodies that have the types of binding
properties that might be useful and effective in a prophylactic vaccine
to HIV-1 [2]. 4E10, 2F5, and 2G12 human mAbs have been widely
studied both because of their broad cross-clade neutralizing proper-
ties, and because their binding epitopes are relatively conserved,
comprising either an oligomannose sequence on gp120 (2G12), or two
different peptide sequences in the membrane proximal external
region (MPER) of gp41 (4E10 and 2F5) (Fig. 1). A possible role of lipids
as part of the antigen binding paratopes of the 4E10 and 2F5mAbswas
raised by reports that themAbs not only bind toMPERof gp41, but also
bind to phospholipids, particularly to 1,3-di(3-sn-phosphatidyl)-sn-
glycerol (cardiolipin) (CL), and also to other phospholipids [3–5].as).
ll rights reserved.Despite this, the binding of 2F5 to phospholipids, including CL, has
been a matter of considerable recent controversy [6]. Two laboratories
failed to conﬁrm any detectable binding to CL [7,8], although some
slight binding to phosphatidylserine was observed at a high antigen
concentration in one laboratory [8]. The lipid polar head group
binding properties of 4E10 and 2F5 are therefore still uncertain.
It is well-known that phospholipids, cholesterol (Chol), and
glycolipids all play important roles in the structure of the HIV-1
envelope, and all of these lipids participate dynamically in the
intracellular assembly of the virion, in the budding process of the
virion from the host cell, and in the fusion or entry process of HIV-1
with target cells [9]. The importance of phospholipids as potentially
useful antigens for inducing neutralizing antibodies to HIV-1 was
further suggested by the observation that a murine mAb (WR304),
that was obtained after immunization with liposomes containing
3-sn-phosphatidylinositol-4-phosphate (PIP) and lipid A as an
adjuvant, neutralized infection of human peripheral blood mono-
nuclear cells (PBMC) [10]. Because 4E10 and 2F5 are both broadly
neutralizing for HIV-1, identiﬁcation of the exact lipid binding
properties of these mAbs may provide insights for design of combined
protein (or peptide) and lipid epitopes that could be included in a
candidate prophylactic vaccine to HIV-1.
Fig. 1. Schematic illustration of binding sites of 2F5, 4E10 to peptide sequences on gp41,
and of 2G12 to oligomannose on gp120 of HIV-1 envelope gp160.
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lipid bilayer of HIV-1, and of the lipid composition of the target or host
cell lipid bilayer membranes that reﬂect the viral lipid composition,
we have examined the binding of 4E10, 2F5, and 2G12 to puriﬁed
phospholipids, and to other types of puriﬁed lipids, by ELISA. We
conﬁrm the binding of both 4E10 and 2F5 to a variety of puriﬁed
phospholipids. However, we have discovered unexpected binding of
4E10 and 2F5 to several puriﬁed glycolipids, and also binding of 4E10
but not 2F5 to puriﬁed cholesterol. In addition, 4E10 but not 2F5
bound strongly to puriﬁed lipid A derived from Gram-negative
bacterial lipopolysaccharide (LPS).
2. Materials and methods
2.1. Lipids, monoclonal antibodies, and ELISA materials
1,2 dimyristoyl-sn-glycero-3-phosphoglycerol (DMPG); 3-sn-
phosphatidylinositol (PI) (soybean); 1,2 dimyristoyl-sn-glycero-3-
phosphate (DMPA); CL; 1,2 dimyristoyl-sn-glycero-3-phosphoetha-
nolamine (DMPE); 1,2 dimyristoyl-sn-glycero-3-phosphoserine
(DMPS); PIP; 3-sn-phosphatidylinositol-4,5-phosphate (PIP2);
(2S,3R,4E)-2-acylaminooctadec-4-ene-3-hydroxy-1-phosphocholine
(sphingomyelin) (SM) (porcine brain); 1,2 dimyristoyl-sn-glycero-3-
phosphate (DMPC); galactosyl ceramide (GalCer); lipid A; ceramide
(Cer); and Chol were purchased from Avanti Polar Lipids. 3-sn-
phosphatidylcholine puriﬁed from egg (Egg PC); Neu5Acα3-
Galβ4GlcCer (GM3); sulfo3GalCer (sulfatide); squalene (SQE), gela-
tin; and BSA were purchased from Sigma Chemical Co. Glucosyl
ceramide (GluCer); Galβ4GlcCer (LacCer); and Galα4Galβ4GlcCer
(Gb3) were purchased from Matreya, LLC. Galβ3GalNAcβ4
(Neu5Acα3)Galβ4GlcCer (GM1) was purchased from Sialomed, Inc.
4E10, 2F5, and 2G12 mAbs were purchased from Polymun Scientiﬁc
Immunbiologische Forschung GmbH. WR304 (formerly known as
PIP4) was puriﬁed from ascites ﬂuid as described [10]. Immulon 2HB
“U” bottom ELISA plates were purchased from Thermolab Systems.
Peroxidase-linked goat anti-mouse IgM (μ-chain speciﬁc) was
purchased from Southern Biotech. Peroxidase-linked sheep anti-
human IgG (γ-chain speciﬁc) was purchased from The Binding Site.
2,2′-azino-di(3-ethylbenzthiazoline-6-sulfonate (ABTS) peroxidase
substrate system was purchased from KPL, Inc.
2.2. Detection of binding of mAbs to lipids by ELISA
Chloroform, chloroform:methanol or methanol stock solutions of
CL, DMPS, DMPA, sulfatide, GalCer, LacCer, PI, PIP, PIP2, GM1, or Gb3were diluted in methanol, and lipid A, Chol, DMPC, Egg PC, DMPE,
DMPG, GluCer, Cer, GM3, and SM were diluted in ethanol, to 10 nmol/
ml, and 1 nmol/well was used as the antigen. Control wells contained
0.1 ml of the appropriate solvent to match the lipid plated. After
evaporation overnight, the plates were blocked with 20 mM Tris–HCl,
154 mM sodium chloride, pH 7.4 (Tris-buffered saline) (TBS)-0.3%
gelatin (except, where indicated with TBS-3% BSA) for 2 h. The ELISA
was performed as described [11]. In brief, mAbs were diluted to
2 μg/ml in blocker and 50 μl/well were plated in 2-fold serial dilutions.
Following incubation for 2 h at room temperature, the plates were
washed with TBS, and 0.1 ml of peroxidase-linked secondary
antibodies (diluted 1:1000) was added. Following a 1 h incubation
and washing with TBS, 0.1 ml/well of ABTS substrate was added. After
1 h plates were read at A405. The ELISA for SQE was adapted from the
previously described method [12]. Sterile round bottom tissue culture
plates (Corning) were coated with 5 nmol/well of SQE diluted in
isopropanol. TBS-0.3% gelatin was used as the blocker and diluent and
the ELISA was conducted as described above. It should be noted that
preparation of TBS-0.3% gelatin was rigorously controlled in order to
prevent large ﬂuctuations between experiments in the background
A405 of methanol- or ethanol-treated wells. TBS-0.3% gelatin was
heated to 65 °C in a water bath and the gelatin was dissolved by
swirling the ﬂask. The solution was cooled to 37 °C in another water
bath and then ﬁltered through a 0.2 μm PES ﬁlter. It was stored at 4 °C
and was used for up to 3 days.
3. Results
3.1. Binding of mAbs to phospholipids
Eleven different puriﬁed phospholipids were used as antigens for
examination by ELISA of the qualitative binding characteristics of
4E10, 2F5, 2G12, and WR304 (Fig. 2). Among the human mAbs, 4E10
bound to nine of the tested phospholipids, 2F5 bound to three, and
2G12 bound to none of the phospholipids. Under the conditions
employed, the strongest binding of 4E10 was observed with four
anionic phospholipids: DMPG, followed by PI, DMPA, and CL. Binding
of 4E10 also occurred with three other anionic phospholipids DMPS,
PIP, and PIP2. Interestingly, DMPE and egg PC, both neutral
phospholipids, were also strongly bound by 4E10, but SM, a neutral
ceramide phosphocholine-containing phospholipid, was not bound
by 4E10.
In contrast to the results with egg PC, DMPC, a saturated PC, was
not bound by 4E10 (Fig. 2). Thus, it appeared that the binding of 4E10,
as determined by ELISA, to phospholipids containing phosphocholine
headgroups can be strongly affected by the fatty acid composition of
the lipid. It is possible that the physical structures of the phospholipid
antigens adsorbed to the microtiter wells were in the form of a
micelles or lipid bilayers, and the surface areas and packing
characteristics of each would be strongly inﬂuenced by the fatty acyl
composition of the lipid. Because of this, it should be noted that
although the binding of the mAbs to different phospholipids, when it
occurs, can be qualitatively determined by ELISA, the relative afﬁnity
of the antigen binding paratope of a given mAb for headgroups of
different phospholipids cannot be quantitatively compared with
different phospholipid antigens.
The 2F5 mAb bound unequivocally to DMPE, and to a lesser
extent to egg PC and DMPS with gelatin as a blocker (Fig. 2). 2F5 also
bound to PI and PIP, but not DMPE, when bovine serum albumin
(BSA) was used as a blocker (data not shown). However, we did not
observe binding of 2F5 to CL when either blocker was used. The
previously reported binding of 2F5 to phospholipids [3,4] is therefore
conﬁrmed, but as also previously reported, the binding of 2F5 to
phospholipids was weaker and sometimes technically difﬁcult to
observe [7,8]. We invariably saw binding of 2F5 to DMPE but,
although binding to DMPS or egg PC was frequently observed,
Fig. 2. Binding of mAbs to phospholipids. The wells were blocked with TBS-0.3% gelatin, except that TBS-3% BSA was used as the blocker and diluent for WR304 binding to egg PC,
DMPC, DMPG and CL. Data are the mean of triplicate determinations (±SD) with background antibody binding to solvent treated wells lacking phospholipid subtracted. Data are
representative of values obtained from 4 to 8 experiments. The data for binding of 2F5 to DMPS and Egg PC overlay each other in the ﬁgure. 2F5 binding to DMPS varied with 4 of 8
experiments yielding data similar to that shown and the other 4 indicating no binding of 2F5 to DMPS.
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binding was probably obscured by unknown variable factors, and it
is likely that the different biophysical states of phospholipid
assemblies that were noted above played a large role in the
quantitative binding characteristics of 2F5 to certain phospholipids.
WR304, a murine mAb, was originally obtained after immuniza-
tionwith liposomes containing PIP and lipid A as an adjuvant, and the
clone was selected for speciﬁc binding to liposomes containing DMPC,
Chol, and PIP, but an inability to react with the same liposomes lacking
PIP [13]. In the present experiments WR304 bound to PIP and, as
previously reported [14], it also cross-reacted with certain other
phospholipids, including PIP2, DMPA, and CL, but not with DMPS
(Fig. 2). Low level binding to CL (four times higher than background)
also occurred, as previously reported [10].
3.2. Binding of mAbs to glycolipids
Among seven glycolipids tested, 4E10 and 2F5, both bound to
GluCer, GalCer, and sulfatide, but did not bind to LacCer, Gb3, GM3, or
GM1 (Fig. 3). WR304 also bound strongly to sulfatide.
3.3. Binding of mAbs to cholesterol and SQE
4E10 and WR304 both bound to Chol, but 2F5 and 2G12 did not
exhibit such binding (Fig. 4A). The binding of both 4E10 andWR304 toFig. 3. Binding of mAbs to glycolipids. Data are the mean of triplicate determinations (±SD) w
Data are representative of values obtained from 4 to 8 experiments. A405 values N2.0 were ass
glycolipids.Chol was unexpected, and this raises the possibility that binding of
each of these mAbs to Chol might be important as a theoretical factor
in the neutralization of HIV-1 by 4E10 and WR304. As mentioned
above, although WR304 was obtained after immunization with
liposomes containing PIP and Chol, the clone was selected for the
inability to recognize liposomes containing Chol but lacking PIP. This is
an example of a binding speciﬁcity of a mAb to puriﬁed Chol that is
strongly inﬂuenced by interfering effects by the surrounding
phospholipids in the lipid bilayer [15].
Binding of the mAbs to SQE, a triperpenoid alkene hydrocarbon
lacking any polar groups, is shown in Fig. 4B. 4E10, 2F5, andWR304 all
bound to SQE, but 2G12 did not bind. These results are compatible
with the proposed hydrophobic interactions of 4E10, 2F5, and WR304
with membranes [4,11].
3.4. Binding of mAbs to lipid A
4E10 andWR304 both unequivocally bound to lipid A, but 2F5 and
2G12 did not exhibit such binding (Fig. 5).
3.5. Absence of binding of 2G12 to lipids
In contrast to 4E10 and 2F5, 2G12, another broadly neutralizing
human IgG1 mAb, that recognizes an oligomannose epitope on gp120
of HIV-1, did not bind to any lipids in our studies. The absence ofith background antibody binding to solvent treated wells lacking glycolipid subtracted.
igned a value of 2.0 for graphing in ordermore effectively show lower levels of binding of
Fig. 4. Binding of mAbs to cholesterol and squalene. (A) Binding to cholesterol. Data are
the mean of triplicate determinations (±SD) with background antibody binding to
ethanol-treated wells lacking cholesterol subtracted. Data are representative of values
obtained from 4 experiments. (B) Binding to squalene. Data are mean of triplicate
determinations (±SD) with background binding to isopropanol-treated wells lacking
squalene subtracted. Data are representative of values from 3 experiments.
Fig. 5. Binding of mAbs to lipid A. Data are the mean of triplicate determinations (±SD)
with background antibody binding to ethanol-treated wells lacking lipid A subtracted.
Data are representative of values obtained from 13 experiments using 4E10, 2F5 and
2G12 and 3 experiments with WR304.
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epitope being at a considerable distance from the lipid bilayer of the
HIV-1 virion [2] (Fig. 1). The lack of lipid binding by 2G12 also
demonstrated that binding of 4E10 and 2F5 to lipids was not simply a
function of nonspeciﬁc binding of IgG1 to lipids.
4. Discussion
In accordance with previous reports that 4E10 binds both to gp41
MPER epitope and to phospholipid, we have found strong and
consistent binding of 4E10 with nine of the eleven anionic and
neutral phospholipid antigens tested. However, as noted earlier (see
Introduction) considerable controversy currently exists regarding
phospholipid headgroup binding speciﬁcities, if any, of the 2F5 mAb
[3–8]. The results of the present study strongly support the concept
that the 2F5 mAb does exhibit distinctive binding to phospholipids.
Among ten phospholipids tested, 2F5 consistently exhibited strong
binding to DMPE. Weaker binding to egg PC and to DMPS was also
generally observed (Fig. 2), but occasionally was not found in a given
experiment. As noted below, with BSA as the blocker, 2F5 also bound
to PI and PIP. In contrast to three reports [3–5] and in support of two
others [7,8] we did not observe binding of 2F5 to either beef heart CL
or synthetic CL (Suppl. Fig. 2).
In our experience, although speciﬁc binding of 2F5 to certain
anionic and neutral phospholipids deﬁnitely occurs, it is also clear
that binding by 2F5, as detected by ELISA, can be easily obscured by
technical issues. For both 4E10 and 2F5, high background levels of
absorbance to polystyrene microtiter wells sometimes occurred in
the absence of antigen (Suppl. Fig. 1). Although the cause of the high
background levels is unknown, whether due to speciﬁc recognition
of polystyrene or to hydrophobic interactions, recognition of this
phenomenon is important. We have also found that other technical
issues, such as the type and particular lot of blocker used, and
perhaps the orientation or self-assembly properties of the phospho-lipids adsorbed to microtiter wells (e.g., the arrangement of
phospholipids in the form of multiple layers or monolayers, or
lipid micelles, or vesicles) can sometimes reduce the resolution for
consistent detection of binding of the 2F5 or 4E10 mAbs to lipids by
ELISA. This might be partly due to a smaller or lower afﬁnity lipid-
binding region that may exist in the paratope of 2F5 when compared
to the binding of the 2F5 paratope to its peptide epitope. It is also
known that in the presence of water the type and charge of lipid
headgroups, the number of fatty acyl groups, and the degree of fatty
acyl unsaturation can all cause dramatic physical changes in the
molecular volume and in the packing and orientation of the fatty
acyl groups of phospholipids, all of which can result in different
ﬂuidity and orientation of the hydrated phospholipid molecules [16].
However, by immunizing with liposomes containing linear peptide
epitopes that are present on gp41, murine mAbs have recently been
produced that recognize unique lipid–peptide patterns [17]. In view
of this it would not be necessarily surprising if different physical
patterns presented by different types and physical states of lipid
antigens could also represent important information for immunolo-
gical recognition of a lipid pattern by lipid-binding antibodies such
as 4E10, 2F5, or WR304.
It is clear that, just as is often found with antibodies to
conformational states of proteins, the binding characteristics of
antibodies to lipids in an ELISA cannot necessarily reproduce the
exact conformational or pattern characteristics that may occur on the
virion. Because of this, although the binding of a mAb to lipids by
ELISA represents important qualitative or even semi-quantitative
immunological information, the inability to control the particulate
physical structures that may occur with different individual pure lipid
antigens adsorbed to microtiter wells prevents rigorous differentia-
tion of relative binding afﬁnities of a given mAb to different lipids or
mixtures of lipids and proteins as they may occur at the surface of the
virion. In view of all of these issues, it is entirely reasonable that
binding of a mAb to a phospholipid, such as 2F5 binding to CL, could
exhibit different binding characteristics under different types of
assays, such as by the use of fully hydrated lipids for inhibition
of the mAb [4], or by surface plasmon resonance (SPR) analysis of
anchored lipids or liposomes [18].
In extension of these studies, we have also discovered consistent
and unequivocal binding of both 4E10 and 2F5 to other types of pure
lipids, and in this respect we have made ﬁve novel observations. First,
4E10 and 2F5mAbs both bound to two neutral glycolipids (GalCer and
GluCer), but not to ceramide alone. Second, 4E10 exhibited strong
binding to an anionic sulfated glycolipid, sulfatide, and 2F5 also
consistently showed unequivocal, but low titer, binding to sulfatide. In
both cases, the binding of the mAb to sulfatide might have occurred as
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the mAb with the sulfate of sulfatide [13]. Third, in addition to
phospholipids and glycolipids, 4E10, but not 2F5, unexpectedly also
bound with apparent very high afﬁnity to Chol.
Fourth, 4E10 and 2F5 both bound to SQE, a hydrophobic alkene
lacking any polar groups that serves as a precursor in the synthesis
of Chol. Naturally-occurring antibodies to SQE have been observed in
humans [12,19], and murine mAbs to SQE have been created [20]. It
was previously hypothesized that the long hydrophobic Ig CDR3
groups of 4E10 and 2F5 might be responsible for interaction with the
lipid bilayer [20,21], perhaps through a hydrophobic patch in the
CDR3 groups [18]. In support of this concept, we have observed low
level, but unequivocal, binding of 4E10, 2F5, and WR304 to SQE as an
antigen. The binding of 4E10 and 2F5 to SQE is consistent with the
hydrophobic patches present in the long CDR3 regions of those
mAbs [4,21,22]. The absence of any detectable binding of 2G12
demonstrates that this was not due to nonspeciﬁc binding of human
IgG1.
Fifth, and perhaps most interestingly, 4E10, but not 2F5 or 2G12,
also exhibited strong binding to lipid A, a complex glycophospholipid
derived from Gram-negative bacterial LPS [23]. Lipid A is the moiety
that provides all of the adjuvant activity of LPS, and it is thought to
serve as a major element of innate immunity [23]. Lipid A has also
served as an adjuvant constituent for numerous candidate and
registered vaccines, including a recently registered hepatitis B vaccine
[24]. In view of the effectiveness of liposomes containing lipid A as a
vaccine formulation [25], and in view of the ability of liposomes
containing lipid A to model the properties of stabilized lipid rafts that
could contain HIV-1 protein and lipid antigens [9], the intriguing
possibility is raised that liposomes containing lipid A could induce
antibodies that emulate the lipid binding properties and also the
neutralizing activity of 4E10 or 2F5.
The results obtained with 4E10 and 2F5 were compared with a
mAb (WR304) that was prepared after immunization of a mouse with
liposomes containing PIP as a phospholipid antigen that was
embedded in a membrane containing neutral and anionic bulk
phospholipids, Chol, and lipid A as an adjuvant [13]. Although
WR304 was selected for the ability to bind to liposomes containing
both PIP and Chol but the inability to bind to the same liposomes
lacking PIP, we have now found that WR304 binds to non-liposomal
pure Chol and SQE by ELISA. Chol is a small antigen that is easily
protected from binding to anti-Chol mAbs by steric hindrance from
surrounding bulk phospholipids [15]. However, since 4E10 and
WR304 both bind strikingly to PIP, Chol, SQE, and lipid A, and since
both mAbs neutralize HIV-1 infection of peripheral blood mono-
nuclear cells [10], the role of a lipid bilayer antigen containing lipid A
as an inducing antigen for 4E10 seems theoretically possible. Recent
studies have further extended this concept by demonstrating that
immunizationwith liposomes containing a protein or peptide antigen
that includes the 4E10 MPER epitope, and that also contain either
phospholipid or glycolipid or Chol as an antigen, and lipid A as an
adjuvant, can be used for immunization of mice to induce multi-
speciﬁc mAbs that, like 4E10, simultaneously and speciﬁcally
recognize both the MPER peptide and the associated lipid antigen in
the lipid bilayer [17,26].
The question could be posed whether some of the broad
neutralizing activities of 4E10 and 2F5 are dependent on the broad
ranges of binding speciﬁcities that they exhibit toward different
types of lipids. Based on studies of MPER peptide that was covalently
conjugated with a linker to the outer surface of liposomes, it was
proposed that binding of 4E10 or 2F5 to the MPER peptide proceeds
through a two step (encounter-docking) conformational change
reaction [18]. The concept of a two step reaction that involves
simultaneous initial binding of 4E10 both to the peptide and to the
adjacent lipid head group, followed by immersion of 4E10 into a lipid
hydrophobic region was also proposed [11], and the presentobservation of binding of 4E10 to SQE is consistent with this latter
hydrophobic docking step in the mechanism. Recently, a second
possible mechanism to explain the two-stage binding properties of
4E10 was proposed that involves the MPER region itself. It was
suggested that the MPER, because of its hydrophobic characteristics,
is partially immersed in the hydrophobic region of the lipid bilayer,
and that the initial binding of 4E10 to the MPER induces a
conformation change in the gp41 protein antigen that results in the
exposure of critical buried hydrophobic MPER amino acid epitopes
that are required for neutralization by 4E10 [27]. However, this latter
theory does not account for the rather dramatic polyreactivity of
4E10 and 2F5 across a range of different types of lipids, including
phospholipids, glycolipids, Chol, and SQE. The theory of MPER
conformation change [27] does not necessarily require binding of
4E10 to lipids, although it does not necessarily exclude such binding.
It also does not explain the neutralizing ability of the murine anti-PIP
mAb (WR304) that exhibits only a one-stage reversible binding
mechanism to liposomal PIP [14]. If the broad neutralizing capabi-
lities of 4E10 were related only to binding of the mAbs to the MPER
peptide sequences, it should be possible to induce broadly neutraliz-
ing antibodies with pure protein or peptide antigens that contain the
appropriate MPER sequences. However, despite much effort little
success has been achieved by this approach [28].
Although the exact origins of 4E10 and 2F5, are unknown, they
were both obtained from HIV-1-infected patients, and both bind
speciﬁcally to well-deﬁned peptide epitopes in the MPER of gp41
of HIV-1 [2]. In mammalian cells CL is normally found only on the
inner membrane of mitochondria [29]. In contrast, CL, DMPG,
DMPE, DMPS, and DMPA are all major constituents of the all of the
membranes of Gram-negative bacterial cells, indeed of virtually all
bacterial membranes [29], and lipid A is uniquely found only in
Gram-negative bacterial cells where it covers the entire outer
leaﬂet of the outer membrane of the cell [23,29]. The discovery of
strong binding of 4E10 to lipid A, CL, DMPG, DMPE, DMPS, and
DMPA, but the absence of binding of 4E10 to SM (which is not
found in Gram-negative bacteria), therefore raises the intriguing
possibility that an opportunistic Gram-negative infection of the
HIV-1-infected patient from which 4E10 was derived might have
played a role the origin of this unique antibody. It might be
speculated that a Gram-negative bacterial cell could have served as
a nonspeciﬁc carrier of HIV-1 during a Gram-negative bacterial
infection, and the bacterial lipid A might have acted as an adjuvant
for innate immunity to induce multi-speciﬁc antibodies that
simultaneously recognized both the bacterial lipids and the HIV-1
envelope protein. This speculation would be consistent with the
observation that murine mAbs having these same types of
multispeciﬁc simultaneous binding properties to lipid and protein
can be experimentally induced by liposomes containing both lipid
A and HIV-1 protein or peptide antigen [17,26].
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